Multi-Scale Models Bridging Levels of Analysis in Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R01 Clinical Trial Not Allowed)
ID: 352211Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/352211

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-016.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for a federal grant titled "Multi-Scale Models Bridging Levels of Analysis in Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)." This funding opportunity aims to develop multi-scale computational models that capture dynamic changes associated with aging and AD/ADRD, utilizing methodologies such as artificial intelligence and machine learning to analyze data across various biological levels. The initiative is critical for enhancing the understanding of aging processes and their impact on AD/ADRD, ultimately informing future research and interventions in public health. Interested applicants can apply for up to $500,000 per year, with a total funding pool of $4 million available for 5-7 grants, and must submit their applications by May 13, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AG-25-016-Full-Announcement.html
    RFA-AG-25-016.html
    The National Institutes of Health (NIH) is inviting applications for a funding opportunity aimed at developing multi-scale computational models related to aging, Alzheimer’s disease (AD), and AD-related dementias (ADRD). This initiative seeks to establish models that encapsulate changes across various biological scales—molecular, cellular, tissue, and behavioral—using methods like artificial intelligence and machine learning. The goal is to harness existing public datasets to understand vulnerabilities and resilience in aging processes affecting AD/ADRD. Key dates include a posted date of February 6, 2024, with a submission deadline of May 13, 2024. Up to $4 million is allocated for funding 5-7 grants, with a maximum budget of $500,000 per year for each application. Eligible applicants include higher education institutions, non-profits, for-profits, governments, and foreign entities. Successful applications will undergo scientific merit reviews based on criteria such as significance, investigator qualifications, innovation, and approach. The overarching aim is not only to bridge computational levels but also to contribute substantially to the understanding of aging and its influence on AD/ADRD, ultimately informing future research and interventions in this critical area of public health.
    Similar Opportunities
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)" aimed at advancing exploratory research in Alzheimer's disease (AD) and related dementias (ADRD). This initiative invites applications for innovative methodologies, animal models, and techniques that require preliminary data, with a focus on addressing health disparities among under-resourced populations. The program emphasizes the importance of interdisciplinary research to combat the public health crisis posed by AD and ADRD, with a maximum funding amount of $275,000 available over two years. Interested applicants must submit their proposals by November 16, 2027, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Artificial Intelligence in Pre-clinical Drug Development for AD/ADRD (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Artificial Intelligence in Pre-clinical Drug Development for AD/ADRD (R01 Clinical Trial Not Allowed)." This initiative invites applications that leverage artificial intelligence (AI) and machine learning (ML) techniques to enhance drug discovery processes for Alzheimer's disease (AD) and related dementias (ADRD), aiming to accelerate the identification and optimization of preclinical drug candidates. The program emphasizes the development of open-source analytical tools and encourages collaboration between academic institutions and biotech/pharma companies to address the complexities of drug discovery. NIH plans to allocate approximately $6 million for 3-4 awards, with individual applications capped at $1 million in direct costs per year over a maximum of five years. Interested applicants should note that the application period opens on January 13, 2025, and closes on February 14, 2025. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" funding opportunity, aimed at supporting innovative research projects that focus on the prevention, diagnosis, treatment, and care for individuals affected by these conditions. This initiative, part of the Small Business Technology Transfer Research (STTR) program, encourages the development of new therapies, devices, and healthcare programs, with an estimated $4 million allocated for approximately ten grants, including maximum budgets of $500,000 for Phase I and $2.5 million for Phase II awards. The funding opportunity underscores the federal commitment to addressing Alzheimer's research challenges through collaboration and innovation in the biomedical field. Interested applicants can find more information and application guidelines at the provided link, with the closing date for submissions set for September 5, 2025.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the R21 exploratory research grant focused on understanding neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD). This funding opportunity aims to enhance knowledge of the neurobiological and behavioral mechanisms underlying symptoms such as aggression, anxiety, and agitation, which significantly impact patient care and outcomes. The initiative is part of a broader national effort to address the complexities of Alzheimer's care, with funding capped at $275,000 over two years, and applications opening on January 16, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD) through the R01 Clinical Trial Optional grant program. This initiative aims to support innovative research that addresses significant biomedical, social, and behavioral aspects of aging, with a focus on inclusivity and diversity in participant recruitment. Given the projected rise in expenditures for AD-related care, which could exceed $1 trillion by 2050, this funding is critical for advancing understanding and treatment of dementia-related challenges. Interested applicants can find more information and submission guidelines at the NIH grants website, with applications due by November 5, 2027, and no specific budget limits outlined.
    Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)." This initiative aims to develop a diverse, interdisciplinary workforce capable of conducting translational research on AD and ADRD, supporting training programs for predoctoral and postdoctoral researchers with varied educational backgrounds. The program emphasizes the importance of interdisciplinary collaboration and aims to enhance understanding and treatment of aging-related health issues. NIH plans to award an estimated 3-5 grants annually over the next three years, with a total budget of $2.7 million, and applications are due by September 25, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), is offering a Small Research Grant Program (R03) aimed at fostering the next generation of researchers in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This program supports innovative projects that enhance understanding, diagnosis, treatment, and care strategies for AD/ADRD, while also promoting workforce diversity and addressing health disparities in this field. Grants of up to $100,000 for a duration of two years are available, with a total of 12 awards expected for fiscal year 2024, amounting to $1.8 million in funding. Interested applicants must be affiliated with eligible organizations and are encouraged to submit their applications by March 16, 2026, with inquiries directed to grantsinfo@nih.gov for further information.
    Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel Therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD)." This initiative aims to streamline the early-stage evaluation of promising pharmacological interventions by bundling independent protocols for phase 1 clinical trials with phase 1b/phase 2a trials, focusing on non-amyloid/non-tau mechanisms that address cognitive and neuropsychiatric symptoms across various stages of the disease. The program is particularly significant given the rising prevalence of Alzheimer's and the associated economic burden, emphasizing the need for innovative treatments as the aging population grows. Eligible applicants include a diverse range of organizations, such as higher education institutions and community-based organizations, with proposals due by November 19, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-226.html.
    Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), has announced the "Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)." This program aims to support innovative research projects focused on Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD), specifically targeting early-stage and diverse researchers who have not previously received significant NIH funding in this field. The initiative is designed to generate pilot data that can lead to larger funding applications, thereby enhancing research capabilities and workforce diversity in biomedical research. Grants of up to $100,000 per year for two years are available, with the application process opening on January 16, 2025, and the closing date set for March 16, 2026. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.